News Results
There are 559,649 News Results
Feb 1, 2024
Key elements of the plan: focus on core businesses, expense reductions and an aggressive share buyback aimed at raising EPS gradually to $3+ in 2028
Feb 1, 2024
MENLO PARK, Calif., Feb. 1, 2024 /PRNewswire/ -- Meta Platforms, Inc. (Nasdaq: META) today reported financial results for the quarter and full year ended December 31, 2023. "We had a...
Feb 7, 2024
ST. LOUIS, Feb. 7, 2024 /PRNewswire/ -- Emerson (NYSE: EMR) today reported results(1) for its first quarter ended December 31, 2023 and updated its full year outlook for fiscal 2024....
Feb 7, 2024
INGREZZA(®) (valbenazine) Fourth Quarter and Full Year 2023 Net Product Sales of $500 Million and $1.84 Billion, Representing Year-over-Year Growth of 25% and 29% Respectively
Feb 7, 2024
Data from FRONTIER 1, a Phase 2b clinical trial, show JNJ-2113, the first and only targeted oral peptide that selectively blocks the IL-23 receptor, achieved the primary and all secondary...
Feb 8, 2024
Fourth Quarter and Full Year 2023 Highlights (compared to Fourth Quarter 2022 unless otherwise noted)
Feb 14, 2024
Q3-2024 Highlights
Feb 14, 2024
DUBLIN, Feb. 14, 2024 /PRNewswire/ -- The "Asia-Pacific Automotive LiDAR System-on-Chip (SoC) Market - Analysis and Forecast, 2024-2033" report has been added to
Feb 14, 2024
Total Revenue of $13.3 Million Total Direct Operating Margin Increased to 59% from 48% Selling, General, and Administrative Expenses Decreased By $2.7 Million, or 30% Adjusted EBITDA of $1.8 Million
Feb 15, 2024
- Priority review designation is based on results from the Phase 3 EV-302 trial, which found enfortumab vedotin plus pembrolizumab significantly extended overall survival and progression free survival compared to...
